Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties.

Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM.

Mol Psychiatry. 2013 Dec;18(12):1236-41. doi: 10.1038/mp.2013.87. Epub 2013 Jul 23. Review.

2.

A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.

Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG.

J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. Review.

PMID:
24388038
3.

A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists.

Duman RS, Li N.

Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2475-84. doi: 10.1098/rstb.2011.0357. Review.

4.

The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.

Chiu CT, Scheuing L, Liu G, Liao HM, Linares GR, Lin D, Chuang DM.

Int J Neuropsychopharmacol. 2014 Dec 28;18(6). pii: pyu102. doi: 10.1093/ijnp/pyu102.

5.

GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine.

Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK.

Neuropsychopharmacology. 2013 Oct;38(11):2268-77. doi: 10.1038/npp.2013.128. Epub 2013 May 17.

6.

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS.

Annu Rev Pharmacol Toxicol. 2014;54:119-39. doi: 10.1146/annurev-pharmtox-011613-135950. Review.

7.

The role of mTOR in depression and antidepressant responses.

Abelaira HM, Réus GZ, Neotti MV, Quevedo J.

Life Sci. 2014 Apr 17;101(1-2):10-4. doi: 10.1016/j.lfs.2014.02.014. Epub 2014 Feb 25. Review.

PMID:
24582593
8.

Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex.

Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ.

Eur Psychiatry. 2014 Sep;29(7):419-23. doi: 10.1016/j.eurpsy.2013.10.005. Epub 2013 Dec 8.

PMID:
24321772
9.

Synaptic mechanisms underlying rapid antidepressant action of ketamine.

Kavalali ET, Monteggia LM.

Am J Psychiatry. 2012 Nov;169(11):1150-6. Review.

PMID:
23534055
10.

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM.

Nature. 2011 Jun 15;475(7354):91-5. doi: 10.1038/nature10130.

11.

Signaling pathways underlying the rapid antidepressant actions of ketamine.

Duman RS, Li N, Liu RJ, Duric V, Aghajanian G.

Neuropharmacology. 2012 Jan;62(1):35-41. doi: 10.1016/j.neuropharm.2011.08.044. Epub 2011 Sep 2. Review.

12.

The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.

Monteggia LM, Gideons E, Kavalali ET.

Biol Psychiatry. 2013 Jun 15;73(12):1199-203. doi: 10.1016/j.biopsych.2012.09.006. Epub 2012 Oct 11. Review.

13.

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr.

J Clin Psychiatry. 2009 Dec;70(12):1662-6. doi: 10.4088/JCP.08m04659. Epub 2009 Sep 8.

14.

[Ketamine's antidepressant effect: focus on ketamine mechanisms of action].

De Maricourt P, Jay T, Goncalvès P, Lôo H, Gaillard R.

Encephale. 2014 Feb;40(1):48-55. doi: 10.1016/j.encep.2013.09.002. Epub 2014 Jan 13. Review. French.

PMID:
24434007
15.

NMDA antagonist treatment of depression.

Williams NR, Schatzberg AF.

Curr Opin Neurobiol. 2016 Feb;36:112-7. doi: 10.1016/j.conb.2015.11.001. Epub 2015 Dec 11. Review.

PMID:
26687375
16.

An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.

Lauterbach EC.

Med Hypotheses. 2012 Jun;78(6):693-702. doi: 10.1016/j.mehy.2012.02.012. Epub 2012 Mar 7.

PMID:
22401777
17.

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS.

Science. 2010 Aug 20;329(5994):959-64. doi: 10.1126/science.1190287.

18.

Sex differences in the antidepressant-like effects of ketamine.

Carrier N, Kabbaj M.

Neuropharmacology. 2013 Jul;70:27-34. doi: 10.1016/j.neuropharm.2012.12.009. Epub 2013 Jan 19.

PMID:
23337256
19.

Targeting of NMDA receptors in the treatment of major depression.

Dang YH, Ma XC, Zhang JC, Ren Q, Wu J, Gao CG, Hashimoto K.

Curr Pharm Des. 2014;20(32):5151-9. Review.

PMID:
24410564
20.

Novel therapeutic strategies in major depression: focus on RNAi and ketamine.

Bortolozzi A, Celada P, Artigas F.

Curr Pharm Des. 2014;20(23):3848-60. Review.

PMID:
24180396

Supplemental Content

Support Center